Chinese biotech firm InnoCare Pharma Ltd. has decided to postpone investor meetings to gauge demand for its Hong Kong initial public offering amid the novel coronavirus outbreak, according to people familiar with the matter.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
